Evidence map›Paper›PMID 26842778›Full record

ArticleActa neuropathologica communications2016

New insights into the protein aggregation pathology in myotilinopathy by combined proteomic and immunolocalization analyses.

A Maerkens, M Olivé, A Schreiner, S Feldkirchner, J Schessl, J Uszkoreit, K Barkovits, A K Güttsches, V Theis, M Eisenacher and 9 more

Open access · goldAbstract read
In one paragraph

Article in Acta neuropathologica communications, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed, 1 pooled it
3.4field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.

  1. Pooled it
  2. Caenorhabditis elegans small heat-shock protein HSP-12.6 has a highly specialized protective function towards muscle thick filaments in vivo.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2026
    Article
  3. Phenotype-specific muscle proteomic profiling in titinopathies.Acta neuropathologica communications · 2026
    Article
  4. Article
  5. Review
  6. Evaluation of aggrephagy markers in myofibrillar myopathies.Acta neuropathologica communications · 2025
    Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Human MutatedInternational journal of molecular sciences · 2023
    Article
  15. Article
  16. SilencingDisease markers · 2023
    Article
  17. Article
  18. Review
  19. Proteomic profiling of sporadic late-onset nemaline myopathy.Annals of clinical and translational neurology · 2022
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 7 institutions in 3 countries.

A MaerkensDepartment of Neurology, Heimer Institute for Muscle Research, University Hospital Bergmannsheil, Ruhr-University Bochum, Buerkle-de-la-Camp-Platz 1, D-44789, Bochum, Germany.
M OlivéDepartment of Pathology and Neuromuscular Unit, Institute of Neuropathology, IDIBELL-Hospital Universitari de Bellvitge and Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Barcelona, Spain.
A SchreinerDepartment of Neurology, Heimer Institute for Muscle Research, University Hospital Bergmannsheil, Ruhr-University Bochum, Buerkle-de-la-Camp-Platz 1, D-44789, Bochum, Germany.
S FeldkirchnerDepartment of Neurology, Friedrich-Baur-Institute, Ludwig-Maximilians University of Munich, D-80336, Munich, Germany.
J SchesslDepartment of Neurology, Friedrich-Baur-Institute, Ludwig-Maximilians University of Munich, D-80336, Munich, Germany.
J UszkoreitMedizinisches Proteom-Center, Ruhr-University Bochum, D-44801, Bochum, Germany.
K BarkovitsMedizinisches Proteom-Center, Ruhr-University Bochum, D-44801, Bochum, Germany.
A K GüttschesDepartment of Neurology, Heimer Institute for Muscle Research, University Hospital Bergmannsheil, Ruhr-University Bochum, Buerkle-de-la-Camp-Platz 1, D-44789, Bochum, Germany.
V TheisMedizinisches Proteom-Center, Ruhr-University Bochum, D-44801, Bochum, Germany.
M EisenacherMedizinisches Proteom-Center, Ruhr-University Bochum, D-44801, Bochum, Germany.
M TegenthoffDepartment of Neurology, Heimer Institute for Muscle Research, University Hospital Bergmannsheil, Ruhr-University Bochum, Buerkle-de-la-Camp-Platz 1, D-44789, Bochum, Germany.
L G GoldfarbClinical Neurogenetics, National Institutes of Health, MSC 9404, Bethesda, MD, USA.
R SchröderInstitute of Neuropathology, University Hospital Erlangen, D-91054, Erlangen, Germany.
B SchoserDepartment of Neurology, Friedrich-Baur-Institute, Ludwig-Maximilians University of Munich, D-80336, Munich, Germany.
P F M van der VenInstitute for Cell Biology, University of Bonn, D-53121, Bonn, Germany.
D O FürstInstitute for Cell Biology, University of Bonn, D-53121, Bonn, Germany.
M VorgerdDepartment of Neurology, Heimer Institute for Muscle Research, University Hospital Bergmannsheil, Ruhr-University Bochum, Buerkle-de-la-Camp-Platz 1, D-44789, Bochum, Germany.
K MarcusMedizinisches Proteom-Center, Ruhr-University Bochum, D-44801, Bochum, Germany.
R A KleyDepartment of Neurology, Heimer Institute for Muscle Research, University Hospital Bergmannsheil, Ruhr-University Bochum, Buerkle-de-la-Camp-Platz 1, D-44789, Bochum, Germany. rudolf.kley@rub.de.
Ruhr University Bochum · DEBG University Hospital Bergmannsheil Bochum · DELudwig-Maximilians-Universität München · DEUniversity of Bonn · DECentro de Investigación Biomédica en Red · ESNational Institutes of Health · USUniversitätsklinikum Erlangen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionMyofibrillar myopathies are characterized by progressive muscle weakness and impressive abnormal protein aggregation in muscle fibers. In about 10 % of patients, the disease is caused by mutations in the MYOT gene encoding myotilin. The aim of our study was to decipher the composition of protein deposits in myotilinopathy to get new information about aggregate pathology.

resultsSkeletal muscle samples from 15 myotilinopathy patients were included in the study. Aggregate and control samples were collected from muscle sections by laser microdissection and subsequently analyzed by a highly sensitive proteomic approach that enables a relative protein quantification. In total 1002 different proteins were detected. Seventy-six proteins showed a significant over-representation in aggregate samples including 66 newly identified aggregate proteins. Z-disc-associated proteins were the most abundant aggregate components, followed by sarcolemmal and extracellular matrix proteins, proteins involved in protein quality control and degradation, and proteins with a function in actin dynamics or cytoskeletal transport. Forty over-represented proteins were evaluated by immunolocalization studies. These analyses validated our mass spectrometric data and revealed different regions of protein accumulation in abnormal muscle fibers. Comparison of data from our proteomic analysis in myotilinopathy with findings in other myofibrillar myopathy subtypes indicates a characteristic basic pattern of aggregate composition and resulted in identification of a highly sensitive and specific diagnostic marker for myotilinopathy.

conclusionsOur findings i) indicate that main protein components of aggregates belong to a network of interacting proteins, ii) provide new insights into the complex regulation of protein degradation in myotilinopathy that may be relevant for new treatment strategies, iii) imply a combination of a toxic gain-of-function leading to myotilin-positive protein aggregates and a loss-of-function caused by a shift in subcellular distribution with a deficiency of myotilin at Z-discs that impairs the integrity of myofibrils, and iv) demonstrate that proteomic analysis can be helpful in differential diagnosis of protein aggregate myopathies.

Indexed as

ImmunohistochemistryMyopathies, Structural, CongenitalProteomicsAgedAged, 80 and overFemaleHumansMaleMass SpectrometryMicroscopy, ConfocalMiddle AgedMuscle ProteinsMuscle, SkeletalMutationProtein Aggregation, PathologicalMuscle Proteins

Identifiers

PMID26842778
PMCPMC4739336
OpenAlexW2264458339

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.